Literature DB >> 31111464

Inclusion of hemimegalencephaly into the phenotypic spectrum of NPRL3 pathogenic variants in familial focal epilepsy with variable foci.

Christina Canavati1, Karl Martin Klein2,3, Zaid Afawi4, Manuela Pendziwiat5, Amal Abu Rayyan1, Lara Kamal1, Fouad Zahdeh1, Ikram Qaysia6, Ingo Helbig5,7, Moien Kanaan1.   

Abstract

Despite tremendous progress through next generation sequencing technologies, familial focal epilepsies are insufficiently understood. We sought to identify the genetic basis in multiplex Palestinian families with familial focal epilepsy with variable foci (FFEVF). Family I with 10 affected individuals and Family II with five affected individuals underwent detailed phenotyping over three generations. The phenotypic spectrum of the two families varied from nonlesional focal epilepsy including nocturnal frontal lobe epilepsy to severe structural epilepsy due to hemimegalencephaly. Whole-exome sequencing and single nucleotide polymorphism array analysis revealed pathogenic variants in NPRL3 in each family, a partial ~38-kb deletion encompassing eight exons (exons 8-15) and the 3'-untranslated region of the NPRL3 gene in Family I, and a de novo nonsense variant c.1063C>T, p.Gln355* in Family II. Furthermore, we identified a truncating variant in the PDCD10 gene in addition to the NPRL3 variant in a patient with focal epilepsy from Family I. The individual also had developmental delay and multiple cerebral cavernomas, possibly demonstrating a digenic contribution to the individual's phenotype. Our results implicate the association of NPRL3 with hemimegalencephaly, expanding the phenotypic spectrum of NPRL3 in FFEVF and underlining that partial deletions are part of the genotypic spectrum of NPRL3 variants. Wiley Periodicals, Inc.
© 2019 International League Against Epilepsy.

Entities:  

Keywords:  NPRL3 gene; epilepsy genetics; hemimegalencephaly

Mesh:

Substances:

Year:  2019        PMID: 31111464     DOI: 10.1111/epi.15665

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  2 in total

1.  AS3MT Polymorphism: A Risk Factor for Epilepsy Susceptibility and Adverse Drug Reactions to Valproic Acid and Oxcarbazepine Treatment in Children From South China.

Authors:  Xiaomei Fan; Yuna Chen; Jieluan Lu; Wenzhou Li; Xi Li; Huijuan Guo; Qing Chen; Yanxia Yang; Hanbing Xia
Journal:  Front Neurosci       Date:  2021-11-26       Impact factor: 4.677

2.  A Multi-Disciplinary Team Approach to Genomic Testing for Drug-Resistant Epilepsy Patients-The GENIE Study.

Authors:  Lata Vadlamudi; Carmen Maree Bennett; Melanie Tom; Ghusoon Abdulrasool; Kristian Brion; Ben Lundie; Hnin Aung; Chiyan Lau; Jonathan Rodgers; Kate Riney; Louisa Gordon
Journal:  J Clin Med       Date:  2022-07-21       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.